Xencor, Inc. (XNCR)

NASDAQ: XNCR · Real-Time Price · USD

7.76

+0.11 (1.44%)

Aug 15, 2025, 12:48 PM - Market open

Revenue by Product

Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2017 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2017 - 2019
Engineered Antibody Therapeutics	110.49M	Log In	Log In	Log In	Log In	Upgrade
Engineered Antibody Therapeutics Growth	-34.36%	Log In	Log In	Log In	Log In	Upgrade

Revenue by Geography

Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2017 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2017 - 2019
United States	110.49M	Log In	Log In	Log In	Log In	Upgrade
United States Growth	-34.36%	Log In	Log In	Log In	Log In	Upgrade
Non-United States	-	Log In	Log In	Log In	Log In	Upgrade
Non-United States Growth	-	Log In	Log In	Log In	Log In	Upgrade